Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Tuesday. The firm issued a sell rating on the stock.

Several other research firms have also issued reports on SYRS. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Trading Up 0.1 %

SYRS stock opened at $0.23 on Tuesday. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The company has a market cap of $6.17 million, a price-to-earnings ratio of -0.08 and a beta of 1.34. The business has a fifty day simple moving average of $0.83 and a 200-day simple moving average of $2.57. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $7.98.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the previous year, the company earned ($1.35) earnings per share. On average, equities research analysts expect that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling at Syros Pharmaceuticals

In related news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at $11,088.90. This represents a 76.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of large investors have recently bought and sold shares of SYRS. GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals in the third quarter valued at $34,000. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter valued at $109,000. Acadian Asset Management LLC lifted its holdings in Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the period. Finally, Exome Asset Management LLC lifted its holdings in Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the period. Institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.